Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966479 | 0.86 | CA2 (0.34) | CA2GABRA1GABRB2 | |
| SCHEMBL21111350 | 0.78 | CA2 (0.46) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL10432656 | 0.77 | PSMB8 (0.36) | GABRA1GABRB2ALDH1A1 | |
| SCHEMBL24422197 | 0.74 | GABRA1 (0.47) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL12395340 | 0.72 | GPR3 (0.50) | CA2ALDH1A1TSHRTDP1KIF11 | |
| SCHEMBL25278479 | 0.71 | HRH4 (0.34) | CA2GABRA1GABRB2ALDH1A1KIF11 | |
| SCHEMBL23621472 | 0.70 | CA2 (0.39) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL23967782 | 0.69 | CA2 (0.38) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL29288722 | 0.69 | POLB (0.46) | ALDH1A1TSHRTDP1 | |
| SCHEMBL3966265 | 0.69 | FAAH (0.34) | CA2GABRA1GABRB2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CA2 2469/4885GABRA1 184/4885GABRB2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.